{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:25:18Z","timestamp":1787430318084,"version":"build-2736575974"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03647-8","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:38:11Z","timestamp":1781721491000},"page":"3737-3755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Complementary Nature of Randomized Controlled Trials and Real-World Evidence Using Over 5\u00a0Years of Experience with Fremanezumab: A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Piero","family":"Barbanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Ramirez Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandra Elizabeth","family":"Guevara Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet","family":"Bhogal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoimhe","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard James","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"3647_CR1","unstructured":"European Medicines Agency (EMA). AJOVY\u00ae Summary of Product Characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ajovy-epar-product-information_en.pdf. Accessed Apr 2025."},{"key":"3647_CR2","unstructured":"US Food and Drug Administration (FDA). AJOVY\u00ae Prescribing Information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761089s000lbl.pdf. Accessed Apr 2025."},{"key":"3647_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/COPD.S244942","volume":"15","author":"DP Tashkin","year":"2020","unstructured":"Tashkin DP, Amin AN, Kerwin EM. Comparing randomized controlled trials and real-world studies in chronic obstructive pulmonary disease pharmacotherapy. Int J Chron Obstruct Pulmon Dis. 2020;15:1225\u201343.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3647_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0333102421989247","volume":"41","author":"HC Diener","year":"2021","unstructured":"Diener HC, Ashina M, Durand-Zaleski I, et al. Health technology assessment for the acute and preventive treatment of migraine: a position statement of the International Headache Society. Cephalalgia. 2021;41:279\u201393.","journal-title":"Cephalalgia"},{"key":"3647_CR5","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e213","volume":"33","author":"HS Kim","year":"2018","unstructured":"Kim HS, Lee S, Kim JH. Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci. 2018;33:e213.","journal-title":"J Korean Med Sci"},{"key":"3647_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1002\/jrsm.1648","volume":"14","author":"M Yao","year":"2023","unstructured":"Yao M, Wang Y, Ren Y, et al. Comparison of statistical methods for integrating real-world evidence in a rare events meta-analysis of randomized controlled trials. Res Synth Methods. 2023;14:689\u2013706.","journal-title":"Res Synth Methods"},{"key":"3647_CR7","unstructured":"US Food and Drug Administration (FDA). Real-World Evidence. 2021. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence. Accessed Apr 2025."},{"key":"3647_CR8","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763\u201374.","journal-title":"Adv Ther"},{"key":"3647_CR9","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/cpt.2083","volume":"109","author":"HG Eichler","year":"2021","unstructured":"Eichler HG, Pignatti F, Schwarzer-Daum B, et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin Pharmacol Ther. 2021;109:1212\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"3647_CR10","unstructured":"European Medicines Agency (EMA). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH E9(R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Step 5. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf. Accessed Apr 2026."},{"key":"3647_CR11","unstructured":"US Department of Health and Human Services. Food and Drug Administration (FDA). Guidance for Industry: E9 Statistical Principles for Clinical Trials. 1998. https:\/\/www.hhs.gov\/guidance\/sites\/default\/files\/hhs-guidance-documents\/FDA\/E9-Statistical-Principles-for-Clinical-Trials.pdf. Accessed Apr 2026."},{"key":"3647_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/02537176241297953","volume":"47","author":"C Andrade","year":"2025","unstructured":"Andrade C. Poorly recognized and uncommonly acknowledged limitations of randomized controlled trials. Indian J Psychol Med. 2025;47:83\u20135.","journal-title":"Indian J Psychol Med"},{"key":"3647_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056560","volume":"8","author":"A Gheorghe","year":"2013","unstructured":"Gheorghe A, Roberts TE, Ives JC, Fletcher BR, Calvert M. Centre selection for clinical trials and the generalisability of results: a mixed methods study. PLoS\u00a0One. 2013;8:e56560.","journal-title":"PLoS\u00a0One"},{"key":"3647_CR14","unstructured":"US Department of Health and Human Services. Food and Drug Administration (FDA). Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry. 2023. https:\/\/www.fda.gov\/media\/171667\/download. Accessed Apr 2026."},{"key":"3647_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1512429","volume":"13","author":"V Costa","year":"2025","unstructured":"Costa V, Custodio MG, Gefen E, Fregni F. The relevance of the real-world evidence in research, clinical, and regulatory decision making. Front Public Health. 2025;13:1512429.","journal-title":"Front Public Health"},{"key":"3647_CR16","unstructured":"US Food and Drug Administration (FDA). Migraine: Developing Drugs for Preventive Treatment- Guidance for Industry. 2023. https:\/\/www.fda.gov\/media\/168871\/download. Accessed Mar 2026."},{"key":"3647_CR17","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102420941839","volume":"40","author":"HC Diener","year":"2020","unstructured":"Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia. 2020;40:1026\u201344.","journal-title":"Cephalalgia"},{"key":"3647_CR18","first-page":"1","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211.","journal-title":"Cephalalgia"},{"key":"3647_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102420919098","volume":"40","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Evers S. International Classification of Headache Disorders - ICHD-4 alpha. Cephalalgia. 2020;40:887\u20138.","journal-title":"Cephalalgia"},{"key":"3647_CR20","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1177\/0333102419877171","volume":"40","author":"MA Chalmer","year":"2020","unstructured":"Chalmer MA, Hansen TF, Lebedeva ER, Dodick DW, Lipton RB, Olesen J. Proposed new diagnostic criteria for chronic migraine. Cephalalgia. 2020;40:399\u2013406.","journal-title":"Cephalalgia"},{"key":"3647_CR21","unstructured":"European Medicines Agency (EMA). Guideline on Clinical Investigation of Medicinal Products for the Treatment of Migraine. 2007. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-migraine_en.pdf. Accessed Mar 2026."},{"key":"3647_CR22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11916-011-0233-z","volume":"16","author":"Z Katsarava","year":"2012","unstructured":"Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep. 2012;16:86\u201392.","journal-title":"Curr Pain Headache Rep"},{"key":"3647_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","volume":"394","author":"MD Ferrari","year":"2019","unstructured":"Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase\u00a03b trial. Lancet. 2019;394:1030\u201340.","journal-title":"Lancet"},{"key":"3647_CR24","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999\u20132008.","journal-title":"JAMA"},{"key":"3647_CR25","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377:2113\u201322.","journal-title":"N Engl J Med"},{"key":"3647_CR26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1092\u2013101.","journal-title":"Headache"},{"key":"3647_CR27","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1102\u201311.","journal-title":"Headache"},{"key":"3647_CR28","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1080\/14740338.2023.2162038","volume":"22","author":"K Hirata","year":"2023","unstructured":"Hirata K, Takeshima T, Imai N, et al. A multicenter, open-label, phase\u00a03 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home. Expert Opin Drug Saf. 2023;22:447\u201354.","journal-title":"Expert Opin Drug Saf"},{"key":"3647_CR29","doi-asserted-by":"crossref","unstructured":"Lipton R, Barbanti P, Ramirez Campos V, et al. Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: results of the UNITE study. Presented at AHS 2023.","DOI":"10.1016\/j.jns.2023.121661"},{"key":"3647_CR30","doi-asserted-by":"crossref","unstructured":"Lipton RB, Ramirez Campos V, Roth-Ben Arie Z, et al. Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: results from the UNITE study (P-231). Presented at AHS 2023.","DOI":"10.1016\/j.jns.2023.121112"},{"key":"3647_CR31","doi-asserted-by":"crossref","unstructured":"McAllister P, Ramirez Campos V, Roth-Ben Arie Z, et al. Impact of fremanezumab treatment on disability outcomes in patients with migraine and major depressive disorder: results of the UNITE study. Presented at AHS 2023.","DOI":"10.1016\/j.jns.2023.121660"},{"key":"3647_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-021-01279-7","volume":"22","author":"M Ashina","year":"2021","unstructured":"Ashina M, Cohen JM, Galic M, et al. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6\u2005months of treatment in the phase\u00a03b FOCUS study. J Headache Pain. 2021;22:68.","journal-title":"J Headache Pain"},{"key":"3647_CR33","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95:e2487\u201399.","journal-title":"Neurology"},{"key":"3647_CR34","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40264-021-01119-2","volume":"44","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Ning X, et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: a multicenter, randomized, open-label study. Drug Saf. 2021;44:1355\u201364.","journal-title":"Drug Saf"},{"key":"3647_CR35","first-page":"74","volume":"42","author":"S Afridi","year":"2022","unstructured":"Afridi S, Totev TI, Krasenbaum LJ, et al. Real-world reductions in monthly migraine days and migraine-related healthcare resource utilization in UK patients using fremanezumab. Cephalalgia. 2022;42:74\u20135.","journal-title":"Cephalalgia"},{"key":"3647_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3390\/pharmaceutics15010293","volume":"15","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Terhart M, Fitzek MP, et al. Change of CGRP plasma concentrations in migraine after discontinuation of CGRP-(receptor) monoclonal antibodies. Pharmaceutics. 2023;15:293.","journal-title":"Pharmaceutics"},{"key":"3647_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s10194-023-01585-2","volume":"24","author":"A Mu\u00f1oz-Vendrell","year":"2023","unstructured":"Mu\u00f1oz-Vendrell A, Campoy S, Caronna E, et al. Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65\u00a0years: a real-life multicentre analysis of 162 patients. J Headache Pain. 2023;24:63.","journal-title":"J Headache Pain"},{"key":"3647_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s10194-023-01561-w","volume":"24","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Egeo G, Aurilia C, et al. Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. J Headache Pain. 2023;24:30.","journal-title":"J Headache Pain"},{"key":"3647_CR39","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/WNF.0000000000000559","volume":"46","author":"A Krymchantowski","year":"2023","unstructured":"Krymchantowski A, Jevoux C, Krymchantowski AG, Silva-N\u00e9to RP. Medication overuse headache, chronic migraine and monoclonal antibodies anti-CGRP: a real-world study. Clin Neuropharmacol. 2023;46:181\u20135.","journal-title":"Clin Neuropharmacol"},{"key":"3647_CR40","doi-asserted-by":"publisher","first-page":"5757","DOI":"10.1007\/s10072-022-06254-x","volume":"43","author":"S Quintana","year":"2022","unstructured":"Quintana S, Russo M, Manzoni GC, Torelli P. Comparison study between erenumab, fremanezumab, and galcanezumab in the preventive treatment of high frequency episodic migraine and chronic migraine. Neurol Sci. 2022;43:5757\u20138.","journal-title":"Neurol Sci"},{"key":"3647_CR41","doi-asserted-by":"publisher","first-page":"1220285","DOI":"10.3389\/fneur.2023.1220285","volume":"14","author":"S Suzuki","year":"2023","unstructured":"Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K. Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol. 2023;14:1220285.","journal-title":"Front Neurol"},{"key":"3647_CR42","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1016\/j.jval.2021.11.101","volume":"25","author":"M Driessen","year":"2022","unstructured":"Driessen M, Patterson-Lomba O, Mu F, et al. POSA28 reductions in migraine and headache days after initiating fremanezumab for patients with migraine and prior use of another monoclonal antibody targeting the CGRP pathway in a US real-world setting. Value Health. 2022;25:S23.","journal-title":"Value Health"},{"key":"3647_CR43","first-page":"419","volume":"29","author":"A Heinze","year":"2022","unstructured":"Heinze A, Totev T, Krasenbaum L, et al. Real-world reductions in migraine and headache days for patients with migraine initiating fremanezumab in Germany. Eur J Neurol. 2022;29:419\u201320.","journal-title":"Eur J Neurol"},{"key":"3647_CR44","unstructured":"Cheng F, Wu Q, Hussain M, Wilksinson V, Khalil M, Ahmend F. Efficacy of fremanezumab in refractory chronic migraine patients: real-world data from the Hull Migraine Clinic, UK. Presented at IHS 2022."},{"key":"3647_CR45","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s10194-021-01358-9","volume":"22","author":"P McAllister","year":"2021","unstructured":"McAllister P, Lamerato L, Krasenbaum LJ, et al. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain. 2021;22:156.","journal-title":"J Headache Pain"},{"key":"3647_CR46","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/head.14528","volume":"63","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Braca S, Sansone M, et al. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine. Headache. 2023;63:788\u201394.","journal-title":"Headache"},{"issue":"1 Suppl","key":"3647_CR47","first-page":"127","volume":"42","author":"F Cohen","year":"2022","unstructured":"Cohen F, Yuan H, Dent K, et al. Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for chronic migraine in a US tertiary headache center. Cephalalgia. 2022;42(1 Suppl):127.","journal-title":"Cephalalgia"},{"issue":"Suppl 1","key":"3647_CR48","first-page":"156","volume":"62","author":"H Yuan","year":"2022","unstructured":"Yuan H, Hopkins M, Driessen MT, Krasenbaum LJ, Seminerio MJ, Marmura MJ. Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab. Headache. 2022;62(Suppl 1):156\u20137.","journal-title":"Headache"},{"key":"3647_CR49","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1111\/ene.15740","volume":"30","author":"AA Argyriou","year":"2023","unstructured":"Argyriou AA, Dermitzakis EV, Xiromerisiou G, et al. Efficacy and safety of fremanezumab for migraine prophylaxis in patients with at least three previous preventive failures: prospective, multicenter, real-world data from a Greek registry. Eur J Neurol. 2023;30:1435\u201342.","journal-title":"Eur J Neurol"},{"key":"3647_CR50","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s13311-023-01394-0","volume":"20","author":"G Lambru","year":"2023","unstructured":"Lambru G, Caponnetto V, Hill B, et al. Long-term effect of switching from an anti-CGRP receptor to an anti-CGRP ligand antibody in treatment-refractory chronic migraine: a prospective real-world analysis. Neurotherapeutics. 2023;20:1284\u201393.","journal-title":"Neurotherapeutics"},{"key":"3647_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1226591","volume":"14","author":"CK Cullum","year":"2023","unstructured":"Cullum CK, Chaudhry BA, Do TP, Amin FM. Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study. Front Neurol. 2023;14:1226591.","journal-title":"Front Neurol"},{"key":"3647_CR52","unstructured":"Ashina M, Mitsikostas D, Amin FM, et al. Real-world effectiveness and safety of fremanezumab in migraine: 3rd interim analysis of the pan-European PEARL study. Presented at EAN 2023."},{"key":"3647_CR53","unstructured":"Tassorelli C, et al. Fremanezumab adherence and persistence along with past and concomitant migraine medication use: PEARL 3rd interim analysis (EPO-582). Presented at EAN 2023."},{"key":"3647_CR54","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000203639","volume":"100","author":"A Straube","year":"2023","unstructured":"Straube A, Br\u00f6ssner G, Gaul C, et al. Fremanezumab for migraine prevention: interim analysis of the non-interventional FINESSE study (P13-12.010). Neurology. 2023;100:3957.","journal-title":"Neurology"},{"key":"3647_CR55","first-page":"927","volume":"62","author":"P Eugeni","year":"2022","unstructured":"Eugeni P, Rooney ME, Saikali NP, et al. Real-world reductions in migraine-related healthcare resource utilization and medication use with fremanezumab treatment in US migraine patients using concomitant acute gepants. Headache. 2022;62:927.","journal-title":"Headache"},{"key":"3647_CR56","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.2169\/internalmedicine.1471-22","volume":"62","author":"Y Ito","year":"2023","unstructured":"Ito Y, Mitsufuji T, Okada M, et al. Early effect of calcitonin gene-related peptide monoclonal antibodies in migraine with medication overuse: a single-center retrospective study. Intern Med. 2023;62:3455\u201360.","journal-title":"Intern Med"},{"key":"3647_CR57","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s10194-022-01396-x","volume":"23","author":"P Barbanti","year":"2022","unstructured":"Barbanti P, Egeo G, Aurilia C, et al. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022;23:46.","journal-title":"J Headache Pain"},{"key":"3647_CR58","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1177\/10600280221118402","volume":"57","author":"L Cantarelli","year":"2023","unstructured":"Cantarelli L, Pestana Grafi\u00f1a D, Gonzalez Perez A, et al. Efficacy and safety of erenumab, galcanezumab, and fremanezumab in the treatment of drug-resistant chronic migraine: experience in real clinical practice. Ann Pharmacother. 2023;57:416\u201324.","journal-title":"Ann Pharmacother"},{"key":"3647_CR59","unstructured":"Teva Branded Pharmaceutical Products R&D Inc. Clinical Study Protocol with Amendment 01 for Placebo-Controlled Study-Episodic Migraine, Study TV48125-CNS-30050. 2016."},{"key":"3647_CR60","unstructured":"Teva Branded Pharmaceutical Products R&D Inc. Clinical Study Protocol with Amendment 01 for Placebo-Controlled Study-Chronic Migraine, Study TV48125-CNS-30049. 2016."},{"key":"3647_CR61","unstructured":"Straube A, Broessner G, Gaul C, et al. Fremanezumab for migraine prevention: interim analysis of the non-interventional FINESSE study. Presented at DGN Kongress 2022."},{"key":"3647_CR62","doi-asserted-by":"crossref","unstructured":"Straube A, Broessner G, Gaul C, et al. Response to fremanezumab for preventive treatment in migraine in routine clinical practice: first data from the FINESSE study. Presented at AHS 2022.","DOI":"10.1212\/WNL.98.18_supplement.1678"},{"key":"3647_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s10194-022-01411-1","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Patterson-Lomba O, et al. Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. J Headache Pain. 2022;23:47.","journal-title":"J Headache Pain"},{"key":"3647_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01415-x","volume":"23","author":"MT Driessen","year":"2022","unstructured":"Driessen MT, Cohen JM, Thompson SF, et al. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain. 2022;23:56.","journal-title":"J Headache Pain"},{"key":"3647_CR65","unstructured":"Ashina M, Mitsikostas D, Amin FM, et al. Real-world effectiveness of fremanezumab with switching from other CGRP pathway targeting mAbs: PEARL study 3rd interim analysis (EPO-075). Presented at EAN 2023."},{"key":"3647_CR66","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1745703","volume":"41","author":"CJ Schankin","year":"2022","unstructured":"Schankin CJ, Broessner G, Gaul C, Kraya T, Hamann X, Haertel B. Response to fremanezumab in migraine patients with or without prior anti-CGRP mAbs - preliminary data from the FINESSE study. Nervenheilkunde. 2022;41:353.","journal-title":"Nervenheilkunde"},{"key":"3647_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01593-2","volume":"24","author":"A Straube","year":"2023","unstructured":"Straube A, Broessner G, Gaul C, et al. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study. J Headache Pain. 2023;24:59.","journal-title":"J Headache Pain"},{"key":"3647_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134526","volume":"12","author":"M Vikelis","year":"2023","unstructured":"Vikelis M, Dermitzakis EV, Xiromerisiou G, et al. Effects of fremanezumab on psychiatric comorbidities in difficult-to-treat patients with chronic migraine: post hoc analysis of a prospective, multicenter, real-world Greek registry. J Clin Med. 2023;12:4526.","journal-title":"J Clin Med"},{"key":"3647_CR69","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4103\/picr.picr_100_24","volume":"15","author":"P Ranganathan","year":"2024","unstructured":"Ranganathan P, Deo V, Pramesh CS. Sample size calculation in clinical research. Perspect Clin Res. 2024;15:155\u20139.","journal-title":"Perspect Clin Res"},{"key":"3647_CR70","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1212\/WNL.0000000000207292","volume":"101","author":"P Barbanti","year":"2023","unstructured":"Barbanti P, Aurilia C, Egeo G, et al. Late response to anti-CGRP monoclonal antibodies in migraine. Neurology. 2023;101:482\u20138.","journal-title":"Neurology"},{"key":"3647_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3233\/BD-2001-14105","volume":"14","author":"KD Miller","year":"2001","unstructured":"Miller KD, Rahman ZU, Sledge GW Jr. Selection bias in clinical trials. Breast Dis. 2001;14:31\u201340.","journal-title":"Breast Dis"},{"issue":"Suppl 1","key":"3647_CR72","first-page":"3S","volume":"118","author":"RB Lipton","year":"2005","unstructured":"Lipton RB, Bigal ME. The epidemiology of migraine. Am J Med. 2005;118(Suppl 1):3S-10S.","journal-title":"Am J Med"},{"key":"3647_CR73","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2024-004102","volume":"32","author":"EJ Alegre-Del Rey","year":"2025","unstructured":"Alegre-Del Rey EJ, F\u00e9nix-Caballero S, Dom\u00ednguez-Santana CM. Switching of anti-migraine antibodies: effectiveness or regression to the mean? Eur J Hosp Pharm. 2025;32:1.","journal-title":"Eur J Hosp Pharm"},{"key":"3647_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0787-1","volume":"18","author":"D Serrano","year":"2017","unstructured":"Serrano D, Lipton RB, Scher AI, et al. Fluctuations in episodic and chronic migraine status over the course of 1\u00a0year: implications for diagnosis, treatment and clinical trial design. J Headache Pain. 2017;18:101.","journal-title":"J Headache Pain"},{"key":"3647_CR75","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1001\/jamainternmed.2013.10391","volume":"173","author":"K Meissner","year":"2013","unstructured":"Meissner K, F\u00e4ssler M, R\u00fccker G, et al. Differential effectiveness of placebo treatments: a systematic review of migraine prophylaxis. JAMA Intern Med. 2013;173:1941\u201351.","journal-title":"JAMA Intern Med"},{"key":"3647_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03300-7","volume":"22","author":"C Xu","year":"2024","unstructured":"Xu C, Zhang F, Doi SAR, et al. Influence of lack of blinding on the estimation of medication-related harms: a retrospective cohort study of randomized controlled trials. BMC Med. 2024;22:83.","journal-title":"BMC Med"},{"key":"3647_CR77","unstructured":"Hern\u00e1n M, Robins J. Causal Inference: What If. 2020. https:\/\/static1.squarespace.com\/static\/675db8b0dd37046447128f5f\/t\/691fb7706ce66332f0b44467\/1763686256720\/hernanrobins_WhatIf_21nov25.pdf. Accessed Mar 2026."},{"key":"3647_CR78","unstructured":"CGRP Education & Research Forum. Reimbursement Europe. 2023. https:\/\/www.cgrpforum.org\/around-half-of-european-countries-reimburse-cgrp-mab-costs\/reimbursement-europe\/. Accessed Mar 2026."},{"key":"3647_CR79","unstructured":"World Health Organization (WHO). Proposal for the addition of fremanezumab to the WHO Model List of Essential Medicines for the preventive treatment of high frequency and chronic migraine in adults: comments from the Department of Mental Health, Brain Health and Substance Use. 2025. https:\/\/cdn.who.int\/media\/docs\/default-source\/2025-eml-expert-committee\/who-dept-comments\/a.13_comments_msd.pdf?sfvrsn=d1df9c48_1&utm. Accessed Mar 2026."},{"key":"3647_CR80","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021\u201339.","journal-title":"Headache"},{"key":"3647_CR81","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s10194-023-01682-2","volume":"24","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Fitzek M, et al. Impact of a reimbursement policy change on treatment with erenumab in migraine\u2014a real-world experience from Germany. J Headache Pain. 2023;24:144.","journal-title":"J Headache Pain"},{"key":"3647_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ph16070934","volume":"16","author":"JB Hong","year":"2023","unstructured":"Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U. A scoping review and meta-analysis of anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals (Basel). 2023;16:934.","journal-title":"Pharmaceuticals (Basel)"},{"key":"3647_CR83","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/s00415-023-12103-4","volume":"271","author":"P Barbanti","year":"2024","unstructured":"Barbanti P, Aurilia C, Egeo G, et al. Ultra-late response (> 24\u00a0weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study. J Neurol. 2024;271:2434\u201343.","journal-title":"J Neurol"},{"key":"3647_CR84","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. J Headache Pain. 2022;23:67.","journal-title":"J Headache Pain"},{"key":"3647_CR85","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1212\/WNL.55.5.629","volume":"55","author":"RB Lipton","year":"2000","unstructured":"Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55:629\u201335.","journal-title":"Neurology"},{"key":"3647_CR86","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40261-025-01433-y","volume":"45","author":"I Hajjaj","year":"2025","unstructured":"Hajjaj I, Baraldi C, Pellesi L. Fremanezumab for the treatment of migraine complicated by medication overuse: a systematic review. Clin Drug Investig. 2025;45:247\u201354.","journal-title":"Clin Drug Investig"},{"issue":"Suppl 2","key":"3647_CR87","first-page":"LP036","volume":"26","author":"AD Hershey","year":"2025","unstructured":"Hershey AD, Szperka CL, Barbanti P, et al. Efficacy and safety of fremanezumab for the preventive treatment of episodic migraine in children and adolescents: a phase\u00a03, randomised, double-blind, placebo-controlled study (abstract). J Headache Pain. 2025;26(Suppl 2):LP036.","journal-title":"J Headache Pain"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03647-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03647-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T20:01:41Z","timestamp":1787428901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03647-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":87,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3647"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03647-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Piero Barbanti has received consulting fees from AbbVie, Allergan, Angelini, Assosalute, Bayer, Eli Lilly, Fondazione Ricerca e Salute, Lundbeck, Orion Pharma, Organon, Pfizer,\u00a0and Teva Pharmaceuticals; has received payment or honoraria from AbbVie, Allergan, Angelini, Bayer, DOC Pharma, Eli Lilly, Lundbeck, Organon, Orion Pharma, Teva Pharmaceuticals,\u00a0and Viatris; has received support for attending meetings and\/or travel from AbbVie, Lundbeck, Teva Pharmaceuticals, and Viatris; has participated on a data safety monitoring board or advisory board for AbbVie, Angelini, Eli Lilly, Lundbeck, Organon, Orion Pharma, Pfizer,\u00a0and Teva Pharmaceuticals; has received other financial or non-financial interests from AbbVie, Amgen, Alder, Allergan, Biohaven, ElectroCore, Eli Lilly, GSK, Lundbeck, New Penta, Noema Pharma, Novartis, and Teva Pharmaceuticals. Timothy Smith received fees for speaker\u2019s bureau from Amgen, AbbVie, Biohaven, Novartis, and Eli Lilly, and for advisory boards or consultancies from AbbVie, Biohaven, Amgen, Eli Lilly, Lundbeck, Impel Neuropharma, Neurolief, Nocira, Nuvie Bio, Theranica, Teva Pharmaceuticals, and Vorso\/Nesos. He has received research support from AbbVie, Aeon, Amgen, BioAge Labs, Biohaven, Charleston Labs, ElectroCore, Eli Lilly, Impel Neuropharma, Lundbeck, Nocira, Novartis, Novo Nordisk, Pfizer, Structure Therapeutics, Teva Pharmaceuticals, Theranica, and Vorso\/Nesos. Richard James Stark has received advisory board and\/or lecture fees from AbbVie, Eli Lilly, Lundbeck, Pfizer, Teva Pharmaceuticals, and Viatris. Verena Ramirez Campos, Maurice Theodoor Driessen, and Alejandra Elizabeth Guevara Morel are employees of Teva Pharmaceuticals. Caroline Ling and Caoimhe Leonard are employees of RTI Health Solutions, which conducted the data collection and analyses that were funded by\u00a0Teva Pharmaceuticals. Preet Bhogal is currently an employee of WEP Clinical and was an employee of RTI Health Solutions at the time the study was undertaken, which conducted the data collection and analyses that were funded by Teva Pharmaceuticals.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals involving any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}